



May 04, 2026

Important Update on RSV Monoclonal Antibodies Administration for Infants

Dear Colleague,

Respiratory syncytial virus (RSV) activity started later than usual and persisted later into the spring in many U.S. regions this season, including in [New York State](#). To continue protection for newborns and infants, the New York State Department of Health (NYSDOH) extended the use of RSV monoclonal antibodies (mAb) for infants through April. As of the end of April, RSV activity decreased to levels similar to those seen in 2025.

Implications for RSV Prevention

The NYSDOH recommendation for routine RSV mAb administration has ended as of April 30, 2026, and does not extend into May 2026. Providers enrolled in the NYSDOH Vaccines for Children (VFC) Program can order additional doses beginning in late summer 2026 and can resume administration for the fall RSV season on October 1. As always, providers may use clinical judgment to determine whether a [higher risk infant](#) should be given RSV mAb off season and can administer from available stock.

As a reminder, infants are eligible for **one** dose of RSV mAb from birth through eight months. If they receive a dose *now*, they will **not** be eligible in the fall/winter next season *unless* they meet the high-risk criteria for administration during their second season.

RSV mAb Recommendations:

Infants less than 8 months of age born during or entering their first RSV season should receive nirsevimab or clesrovimab if:

- Pregnant parent did not receive RSVpreF (Abrysvo) vaccine during this pregnancy,
- Pregnant parent's RSV vaccination status is unknown, or
- Infant was born <14 days after the pregnant parent's RSVpreF (Abrysvo) vaccination

Children aged 8 months through 19 months who are at increased risk of severe RSV disease when entering their second season remain eligible.

- Only nirsevimab is recommended as a first and second dose. Clesrovimab can only be used for the first dose.

Infants who received RSV-mAb during the 2025-26 season should not receive an additional dose in the 2026-27 season unless they meet criteria for increased risk in their second RSV season.

Maternal RSV vaccination for the 2025-26 respiratory virus season concluded on January 31, and continued use is not recommended.

Please email immunize@health.ny.gov if you have any questions.

Thank you for your work in caring for the youngest New Yorkers.

Sincerely,

Debra Blog, MD, MPH
Medical Director, Division of Vaccine Excellence
New York State Department of Health

Resources

- Centers for Disease Control and Prevention (CDC): [Administration Using Clinical Judgement](#)
- American Academy of Pediatrics (AAP): [RSV Immunization Administration](#)
- NYSDOH: [New York State Respiratory Surveillance and Reports](#)